Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
Merck
McKinsey
Colorcon

Last Updated: May 28, 2023

KINEVAC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Kinevac patents expire, and when can generic versions of Kinevac launch?

Kinevac is a drug marketed by Bracco and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sincalide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kinevac

A generic version of KINEVAC was approved as sincalide by MAIA PHARMS INC on November 22nd, 2022.

  Try a Trial

Drug patent expirations by year for KINEVAC
Drug Prices for KINEVAC

See drug prices for KINEVAC

Recent Clinical Trials for KINEVAC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Penn State UniversityN/A
Memorial Health University Medical CenterN/A
Temple UniversityN/A

See all KINEVAC clinical trials

Pharmacology for KINEVAC
Anatomical Therapeutic Chemical (ATC) Classes for KINEVAC

US Patents and Regulatory Information for KINEVAC

KINEVAC is protected by one US patents.

Patents protecting KINEVAC

Sincalide formulations
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco KINEVAC sincalide INJECTABLE;INJECTION 017697-001 Approved Prior to Jan 1, 1982 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for KINEVAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco KINEVAC sincalide INJECTABLE;INJECTION 017697-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Bracco KINEVAC sincalide INJECTABLE;INJECTION 017697-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for KINEVAC

See the table below for patents covering KINEVAC around the world.

Country Patent Number Title Estimated Expiration
Japan S4813114 ⤷  Try a Trial
Denmark 132074 ⤷  Try a Trial
European Patent Office 1631305 FORMULATIONS A BASE DE SINCALIDE (SINCALIDE FORMULATIONS) ⤷  Try a Trial
Australia 2003304382 Sincalide formulations ⤷  Try a Trial
Canada 2503982 FORMULATIONS A BASE DE SINCALIDE (SINCALIDE FORMULATIONS) ⤷  Try a Trial
France 2007810 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
McKinsey
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.